US bars imports from Chinese genomics giants ahead of the Shenzhen summit

The decision presumes the three companies' goods are prohibited. An importer can bring them into the US only by proving, with clear and convincing evidence, that no forced labour was involved. Asia Times writes that the scope is wider than the Biosecure Act. That law restricts only federal contracts and grants, while the list reaches all imports of sequencers, reagents and other products. According to CLP, the impact could spread to US clinical laboratories, sequencing facilities and diagnostics developers. The department had added 43 entities on 31 July, calling it the largest single expansion; Asia Times dates the same increase to August.

Market share shows the limits of the impact: according to Asia Times, Illumina holds about 70% of the global sequencer market and MGI 7–10%. The department did not make its evidence public; BGI rejected the accusation and said it expected no significant impact on its business. China's commerce ministry argued that the decision ran counter to the consensus of the two leaders. Foreign ministry spokesman Guo Jiakun said necessary measures would be taken, but did not directly answer a question on the effect on the talks.

The timing is the real story. The decision came about two weeks before the Xi–Trump meeting expected in Shenzhen in November and the export-control timetable of 9–10 November. Washington is thus preserving the truce on the export side while keeping up pressure on imports under a separate legal authority. There is no official finding on whether the decision breaches the truce text.